IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19
Ano de defesa: | 2023 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Fundação Universidade Federal de Mato Grosso do Sul
|
Programa de Pós-Graduação: |
Não Informado pela instituição
|
Departamento: |
Não Informado pela instituição
|
País: |
Brasil
|
Palavras-chave em Português: | |
Link de acesso: | https://repositorio.ufms.br/handle/123456789/6978 |
Resumo: | COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus, with a global impact. Several research studies have been conducted to find vaccines to prevent the infection, among which AstraZeneca, CoronaVac, and BNT162b2 have been administered in Brazil. The Bacille Calmette-Guérin (BCG) vaccine, used against tuberculosis, has shown in studies to offer protection against non-specific pathogens, activating macrophages, phagocytes and pro-inflammatory cytokines, possessing antiviral activity. This non-specific antiviral activity led to an interest in investigating whether this vaccine could provide some protection against SARS-CoV-2. Therefore, the objective of this study was to quantify seroconversion and antibody levels produced by vaccines available in the Brazilian market, considering the influence of BCG vaccination. A total of 874 healthcare workers over 18 years of age were selected and divided into groups for the AZD1222 vaccine (n=592), CoronaVac (n=264), and Pfizer (n=18), each with subdivisions between those who received the placebo and those who received BCG. A quantitative and qualitative test of anti-spike IgG was performed using a chemiluminescent microparticle immunoassay on serum samples collected 28 days after vaccination. The group that received the Pfizer vaccine had a reduced number of participants, and therefore, their results were excluded from the statistical analysis. The study found that the levels of anti-spike IgG antibodies were two times higher in the AZD1222 vaccine compared to CoronaVac (geometric mean ratio (GMR) 2.58, 95% confidence interval (CI)) with two doses. When comparing two doses of CoronaVac with one dose of AZD1222, the result was similar (GMR 0.99, 95% CI). The presence of BCG (BCG group n=435; saline placebo n=439) did not induce an increase in antibodies against SARS-CoV-2 in both groups (AZD1222 p=0.38; CoronaVac p=0.76). Therefore, it is concluded that the presence of the BCG vaccine did not increase protection mediated by antibodies against COVID-19, and the AZD1222 vaccine induced twice as many antibodies as the CoronaVac vaccine. |
id |
UFMS_9d67cc6163bcb66cf421d813190daf9e |
---|---|
oai_identifier_str |
oai:repositorio.ufms.br:123456789/6978 |
network_acronym_str |
UFMS |
network_name_str |
Repositório Institucional da UFMS |
repository_id_str |
|
spelling |
2023-11-22T19:31:58Z2023-11-22T19:31:58Z2023https://repositorio.ufms.br/handle/123456789/6978COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus, with a global impact. Several research studies have been conducted to find vaccines to prevent the infection, among which AstraZeneca, CoronaVac, and BNT162b2 have been administered in Brazil. The Bacille Calmette-Guérin (BCG) vaccine, used against tuberculosis, has shown in studies to offer protection against non-specific pathogens, activating macrophages, phagocytes and pro-inflammatory cytokines, possessing antiviral activity. This non-specific antiviral activity led to an interest in investigating whether this vaccine could provide some protection against SARS-CoV-2. Therefore, the objective of this study was to quantify seroconversion and antibody levels produced by vaccines available in the Brazilian market, considering the influence of BCG vaccination. A total of 874 healthcare workers over 18 years of age were selected and divided into groups for the AZD1222 vaccine (n=592), CoronaVac (n=264), and Pfizer (n=18), each with subdivisions between those who received the placebo and those who received BCG. A quantitative and qualitative test of anti-spike IgG was performed using a chemiluminescent microparticle immunoassay on serum samples collected 28 days after vaccination. The group that received the Pfizer vaccine had a reduced number of participants, and therefore, their results were excluded from the statistical analysis. The study found that the levels of anti-spike IgG antibodies were two times higher in the AZD1222 vaccine compared to CoronaVac (geometric mean ratio (GMR) 2.58, 95% confidence interval (CI)) with two doses. When comparing two doses of CoronaVac with one dose of AZD1222, the result was similar (GMR 0.99, 95% CI). The presence of BCG (BCG group n=435; saline placebo n=439) did not induce an increase in antibodies against SARS-CoV-2 in both groups (AZD1222 p=0.38; CoronaVac p=0.76). Therefore, it is concluded that the presence of the BCG vaccine did not increase protection mediated by antibodies against COVID-19, and the AZD1222 vaccine induced twice as many antibodies as the CoronaVac vaccine.A COVID-19 é uma doença infecciosa causada pelo Coronavírus SARS-CoV-2, com impacto global. Diversas pesquisas foram conduzidas em busca de vacinas para prevenir a infecção, das quais, a AstraZeneca, CoronaVac e BNT162b2 foram aplicadas no Brasil. A vacina Bacilo de Calmette e Guérin (BCG), utilizada contra a tuberculose, demonstrou em estudos proteger contra patógenos inespecíficos, ativando macrófagos, fagócitos e citocinas pró-inflamatória, possuindo atividade antiviral. Essa atividade antiviral inespecífica levou a um interesse em investigar se essa vacina poderia oferecer alguma proteção contra o SARS-CoV-2. Com isso, o objetivo do presente estudo foi quantificar a soroconversão e os níveis de anticorpos produzidos pelas vacinas disponíveis no mercado brasileiro, considerando a influência da vacinação com a BCG. Foram selecionados 874 trabalhadores da saúde com idade acima de 18 anos e divididos em grupos para as vacinas AZD1222 (n=592), CoronaVac (n=264) e Pfizer (n=18), cada um com subdivisão entre aqueles que receberam o placebo e aqueles que receberam a BCG. Realizou-se teste quantitativo e qualitativo de anti-spike IgG, utilizando um ensaio quimioluminescente de micropartículas imunológicas no soro coletado 28 dias após a vacinação. O grupo que recebeu a vacina Pfizer apresentou um número reduzido de participantes, e portanto, seus resultados foram excluídos da análise estatística. O estudo encontrou os níveis de anticorpos anti-spike IgG duas vezes mais elevados na vacina AZD1222 em comparação com a CoronaVac (geometric mean ratio (GMR) 2,58, 95% intervalo de confiança (IC)) com duas doses, e quando comparado duas doses da CoronaVac com uma dose de AZD1222, o resultado foi similar (GRM 0,99, 95% IC). A presença da BCG (grupo BCG n=435; placebo salina n=439) não induziu o aumento de anticorpos contra SARS-CoV-2 em ambos os grupos (AZD1222 p=0,38; CoronaVac p=0,76). Com isso, conclui-se que a presença da vacina BCG não aumentou a proteção mediada por anticorpos contra a COVID-19, e a vacina AZD1222 induziu duas vezes mais anticorpos que a CoronaVac.Fundação Universidade Federal de Mato Grosso do SulUFMSBrasilAnticorpos. Doença pelo Novo Coronavírus (2019-nCoV). Pessoal da Saúde. Vacinas. Vacina BCG.IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisJulio Henrique Rosa CrodaMariana Gazzoni Sperottoinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMSinstname:Universidade Federal de Mato Grosso do Sul (UFMS)instacron:UFMSORIGINALDISSERTAÇÃO-Mariana Gazzoni Sperotto.pdfDISSERTAÇÃO-Mariana Gazzoni Sperotto.pdfapplication/pdf1821818https://repositorio.ufms.br/bitstream/123456789/6978/-1/DISSERTA%c3%87%c3%83O-Mariana%20Gazzoni%20Sperotto.pdf542ec541c9a312212f492c19bc9c91eeMD5-1123456789/69782023-11-22 15:32:04.634oai:repositorio.ufms.br:123456789/6978Repositório InstitucionalPUBhttps://repositorio.ufms.br/oai/requestri.prograd@ufms.bropendoar:21242023-11-22T19:32:04Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)false |
dc.title.pt_BR.fl_str_mv |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
title |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
spellingShingle |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 Mariana Gazzoni Sperotto Anticorpos. Doença pelo Novo Coronavírus (2019-nCoV). Pessoal da Saúde. Vacinas. Vacina BCG. |
title_short |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
title_full |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
title_fullStr |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
title_full_unstemmed |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
title_sort |
IMPACTO DA VACINAÇÃO PRÉVIA COM BCG NA RESPOSTA ANTI-SPIKE IGG EM PROFISSIONAIS DE SAÚDE IMUNIZADOS COM DIFERENTES VACINAS CONTRA COVID-19 |
author |
Mariana Gazzoni Sperotto |
author_facet |
Mariana Gazzoni Sperotto |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Julio Henrique Rosa Croda |
dc.contributor.author.fl_str_mv |
Mariana Gazzoni Sperotto |
contributor_str_mv |
Julio Henrique Rosa Croda |
dc.subject.por.fl_str_mv |
Anticorpos. Doença pelo Novo Coronavírus (2019-nCoV). Pessoal da Saúde. Vacinas. Vacina BCG. |
topic |
Anticorpos. Doença pelo Novo Coronavírus (2019-nCoV). Pessoal da Saúde. Vacinas. Vacina BCG. |
description |
COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus, with a global impact. Several research studies have been conducted to find vaccines to prevent the infection, among which AstraZeneca, CoronaVac, and BNT162b2 have been administered in Brazil. The Bacille Calmette-Guérin (BCG) vaccine, used against tuberculosis, has shown in studies to offer protection against non-specific pathogens, activating macrophages, phagocytes and pro-inflammatory cytokines, possessing antiviral activity. This non-specific antiviral activity led to an interest in investigating whether this vaccine could provide some protection against SARS-CoV-2. Therefore, the objective of this study was to quantify seroconversion and antibody levels produced by vaccines available in the Brazilian market, considering the influence of BCG vaccination. A total of 874 healthcare workers over 18 years of age were selected and divided into groups for the AZD1222 vaccine (n=592), CoronaVac (n=264), and Pfizer (n=18), each with subdivisions between those who received the placebo and those who received BCG. A quantitative and qualitative test of anti-spike IgG was performed using a chemiluminescent microparticle immunoassay on serum samples collected 28 days after vaccination. The group that received the Pfizer vaccine had a reduced number of participants, and therefore, their results were excluded from the statistical analysis. The study found that the levels of anti-spike IgG antibodies were two times higher in the AZD1222 vaccine compared to CoronaVac (geometric mean ratio (GMR) 2.58, 95% confidence interval (CI)) with two doses. When comparing two doses of CoronaVac with one dose of AZD1222, the result was similar (GMR 0.99, 95% CI). The presence of BCG (BCG group n=435; saline placebo n=439) did not induce an increase in antibodies against SARS-CoV-2 in both groups (AZD1222 p=0.38; CoronaVac p=0.76). Therefore, it is concluded that the presence of the BCG vaccine did not increase protection mediated by antibodies against COVID-19, and the AZD1222 vaccine induced twice as many antibodies as the CoronaVac vaccine. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-11-22T19:31:58Z |
dc.date.available.fl_str_mv |
2023-11-22T19:31:58Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufms.br/handle/123456789/6978 |
url |
https://repositorio.ufms.br/handle/123456789/6978 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Fundação Universidade Federal de Mato Grosso do Sul |
dc.publisher.initials.fl_str_mv |
UFMS |
dc.publisher.country.fl_str_mv |
Brasil |
publisher.none.fl_str_mv |
Fundação Universidade Federal de Mato Grosso do Sul |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMS instname:Universidade Federal de Mato Grosso do Sul (UFMS) instacron:UFMS |
instname_str |
Universidade Federal de Mato Grosso do Sul (UFMS) |
instacron_str |
UFMS |
institution |
UFMS |
reponame_str |
Repositório Institucional da UFMS |
collection |
Repositório Institucional da UFMS |
bitstream.url.fl_str_mv |
https://repositorio.ufms.br/bitstream/123456789/6978/-1/DISSERTA%c3%87%c3%83O-Mariana%20Gazzoni%20Sperotto.pdf |
bitstream.checksum.fl_str_mv |
542ec541c9a312212f492c19bc9c91ee |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS) |
repository.mail.fl_str_mv |
ri.prograd@ufms.br |
_version_ |
1801678660895244288 |